T1	Participants 94 172	patients with type 2 diabetes inadequately controlled by metformin monotherapy
T2	Participants 471 500	patients with type 2 diabetes
T3	Participants 646 737	302 patients with type 2 diabetes (mean A1C 8.3%) on metformin monotherapy (mean 1.5 g/day)
